Migraine Pill’s Price Tag Under the Microscope: Atogepant Cost-Effectiveness Tested in Taiwan

Migraine is far more than a bad headache. For the hundreds of millions of people worldwide who live with episodic migraine, defined as fewer than fifteen headache days per month, the condition erodes productivity, disrupts family life, and consumes health system resources in a quiet but relentless way. Preventive therapies have long been limited to blood pressure drugs, antidepressants, and anticonvulsants that were never designed for migraine, leaving a persistent gap between what patients need and what medicine can offer. That gap began to close with the arrival of calcitonin gene-related peptide, or CGRP, inhibitors, a class of drugs developed specifically to interrupt the molecular signaling that drives migraine attacks. Atogepant, an oral CGRP receptor antagonist taken once daily, is one of the newest members of this class, and its clinical benefits are well documented. What has been far less clear, particularly for health systems outside North America and Europe, is whether those benefits justify the price.

A new study published in BMC Health Services Research offers one of the first answers to that question for Taiwan. A team of researchers from the National Defense Medical University and Tri-Service General Hospital, led by corresponding author Ping-Hsuan Hsieh, constructed a formal economic evaluation comparing atogepant with placebo for the preventive treatment of episodic migraine in adults, viewed entirely through the lens of Taiwan’s National Health Insurance system. The work matters because cost-effectiveness is intensely local. A drug that looks like a bargain in one country can look extravagant in another, depending on drug prices, health care utilization patterns, and, crucially, how much a society is willing to pay for an additional year of good health.

The methodological backbone of the study is a Markov model, a standard but powerful tool in health economics. Markov models divide a population into discrete health states and then simulate how individuals move between those states over time, with each transition governed by a probability drawn from clinical trial data. In this case, the researchers defined health states by monthly migraine days, the metric that both clinicians and regulators use to judge whether a preventive therapy is working. Patients cycled through the model in twelve-week intervals over a one-year horizon, a design that mirrors the typical duration of the pivotal trials and keeps the extrapolation burden modest. Treatment discontinuation was built into the model, acknowledging that real-world patients stop preventive drugs far more often than trial participants do.

The clinical engine of the model came from the Phase III ADVANCE trial, the landmark randomized study that established atogepant’s efficacy for episodic migraine. In that trial, patients receiving atogepant experienced meaningful reductions in monthly migraine days compared with placebo, and the transition probabilities derived from those results allowed the Taiwanese team to project how a treated population would distribute across health states over the simulated year. On the cost side, the researchers turned to a source that gives the analysis its local credibility: Taiwan’s National Health Insurance claims data. Rather than importing cost estimates from foreign settings, they extracted real reimbursement figures for outpatient visits, emergency department use, and hospitalization, capturing the actual resource consumption of migraine patients within the system that would ultimately pay for the drug.

The benefits side of the ledger was measured in quality-adjusted life-years, or QALYs, the workhorse metric of cost-utility analysis. A QALY combines survival with health-related quality of life, weighting each year of life by the quality of that year on a scale where one represents perfect health and zero represents death. Migraine rarely kills, which makes the quality-of-life component dominant in this disease area. Patients in the model accrued utility according to their migraine frequency state, with fewer monthly migraine days translating into higher quality of life. Here, however, the researchers confronted a familiar problem in health technology assessment: Taiwan lacks its own utility values for migraine frequency states, so the model had to rely on non-local utility inputs, a limitation that would prove central to interpreting the results.

The base-case findings placed atogepant in an interesting middle zone. Compared with placebo, atogepant generated an incremental cost of 1,766 US dollars and a gain of 0.032 QALYs over the one-year horizon, yielding an incremental cost-effectiveness ratio, or ICER, of 55,749 US dollars per QALY gained. To make sense of that number, health economists conventionally benchmark ICERs against a country’s gross domestic product per capita, a practice popularized by the World Health Organization’s historical guidelines. Taiwan’s GDP per capita stands at roughly 34,040 US dollars, so the atogepant ICER fell between one and two times GDP per capita. Under that framework, the drug is not automatically considered cost-effective at the strictest threshold of one times GDP, but it sits comfortably within the range that many health systems treat as potentially acceptable, particularly for therapies addressing conditions with substantial unmet need.

Because every economic model rests on assumptions that may not hold, the researchers subjected their results to a battery of sensitivity analyses. Deterministic one-way analysis, which varies each parameter individually while holding the rest constant, revealed that the single most influential driver of cost-effectiveness was the utility value assigned to the healthiest state in the model, the state of having zero to three monthly migraine days. This finding is intuitive once unpacked: if avoiding migraines produces only a small quality-of-life improvement, then the QALY gain from an effective preventive drug shrinks, and the cost per QALY balloons. If it produces a large improvement, the opposite occurs. Since that utility value was imported rather than measured locally, the entire cost-effectiveness conclusion hinges on a number that may or may not reflect how Taiwanese patients actually experience migraine freedom.

The probabilistic sensitivity analysis added a second layer of nuance by running the model thousands of times while simultaneously sampling every parameter from its uncertainty distribution. The result was a cost-effectiveness acceptability curve showing how the probability that atogepant is cost-effective changes as society’s willingness to pay rises. At a threshold of one times Taiwan’s GDP per capita, atogepant had only a 2.9 percent chance of being cost-effective. At two times GDP per capita, that probability climbed to 74.4 percent, and at three times GDP per capita it reached 96.0 percent. The tipping point, where the probability crossed fifty percent, came at a willingness to pay of approximately 56,300 US dollars per QALY. In plain terms, whether atogepant is a good buy depends almost entirely on how much value Taiwan’s health system assigns to relieving the burden of episodic migraine, and the drug becomes the more likely-than-not choice just above the two-times-GDP threshold.

The authors are appropriately candid about the limits of their work, describing the study as a baseline, proof-of-concept assessment rather than a definitive verdict. Beyond the reliance on non-local utility values, the comparison against placebo, while methodologically clean, sidesteps the question that payers ultimately care about most: how atogepant performs against the preventive therapies already in use, from older oral agents to the injectable CGRP monoclonal antibodies. The one-year horizon, chosen to align with trial evidence, also cannot capture longer-term effects, and the model did not incorporate indirect costs such as lost workplace productivity, which for migraine are often larger than direct medical costs. The researchers call for future evaluations to integrate Taiwan-specific quality-of-life data and to employ network meta-analyses positioning atogepant against active comparators.

Even with those caveats, the study marks a meaningful step for evidence-based drug policy in Asia. Taiwan’s National Health Insurance is renowned for delivering universal coverage at remarkably low administrative cost, but that efficiency depends on disciplined decisions about which new technologies to adopt. By grounding an atogepant evaluation in local claims data and transparent GDP-based thresholds, the research team has created a template that other middle- and high-income health systems can adapt, while simultaneously flagging exactly where local data collection, particularly patient-reported quality of life across migraine frequency states, would deliver the greatest payoff. For the millions of people whose migraines could be prevented by CGRP-targeted therapy, the message is one of cautious optimism: the science works, the economics are within reach, and the remaining uncertainty is now precisely mapped for the next generation of studies to resolve.

Subject of Research: Cost-effectiveness evaluation of atogepant versus placebo for preventive treatment of episodic migraine in Taiwan

Article Title: Economic evaluation of atogepant compared to placebo for the preventive treatment of episodic migraine in Taiwan

Article References: Fang, C.-Y., Lin, T.-K., Yang, F.-C., Liu, Y., Ruan, Y.-Z., & Hsieh, P.-H. (2026). Economic evaluation of atogepant compared to placebo for the preventive treatment of episodic migraine in Taiwan. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15776-5

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15776-5

Keywords: atogepant, CGRP antagonist, episodic migraine, cost-effectiveness, health economics, QALY, ICER, Markov model, Taiwan National Health Insurance, migraine prevention, pharmacoeconomics, health technology assessment